Evidence map›Paper›PMID 38529853›Full record

ArticleJournal of veterinary internal medicine

A randomized placebo-controlled double-blinded study comparing oral and subcutaneous administration of mistletoe extract for the treatment of equine sarcoid disease.

Anke Beermann, Ophélie Clottu, Marcus Reif, Ulrike Biegel, Lucia Unger, Christoph Koch

Open access · goldAbstract readRandomized Controlled Trial, Veterinary
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Anke BeermannResearch Institute of Organic Agriculture (FiBL), Department of Livestock Sciences, Frick, Switzerland.ORCID https://orcid.org/0009-0007-4943-5151
Ophélie ClottuResearch Institute of Organic Agriculture (FiBL), Department of Livestock Sciences, Frick, Switzerland.
Marcus ReifSociety of Clinical Research e.V, Berlin, Germany.
Ulrike BiegelResearch Institute of Organic Agriculture (FiBL), Department of Livestock Sciences, Frick, Switzerland.
Lucia UngerDepartment of Clinical Veterinary Medicine, Swiss Institute of Equine Medicine (ISME), University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0001-8238-8907
Christoph KochDepartment of Clinical Veterinary Medicine, Swiss Institute of Equine Medicine (ISME), University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-4574-6952
Forschungsinstitut für Biologischen Landbau · CHUniversity of Bern · CHSociety for Clinical Research · DE

Funding

The Rudolf Steiner Fund for Scientific Research e.V., Nuremberg, GermanyThe Society of Cancer Research, Arlesheim, SwitzerlandThe Swiss Veterinary Association for Alternative and Complementary Medicine (camvet.ch), Bern, SwitzerlandThe Veterinary Association of the Canton of Neuchâtel, Neuchâtel, Switzerland
6 · The paper itself

Abstract

backgroundEquine sarcoids (ES) are the most common cutaneous tumors in equids. Systemic treatment options are sparse. Subcutaneous (SC) injections of Viscum album extract (VAE) demonstrate efficacy as a systemic treatment directed against ES. OBJECTIVES/

aimTo critically assess the therapeutic efficacy of orally administered VAE. ANIMALS: Forty-five ES-affected, privately owned, 3-12 year-old horses.

methodsA 3-armed randomized placebo-controlled, double-blinded study was conducted in a double-dummy design. Horses were subjected to oral administration and SC injections of either VAE or placebo (VAE oral/placebo SC, VAE SC/placebo oral, placebo oral/placebo SC) over a 7-month treatment period. Primary endpoint was the change of baseline of a composite index of ES number and ES area after 14 months. Second endpoint was the clinical response.

resultsNo statistically significant difference in the composite endpoint between the 3 study arms was found. The primary endpoint showed 4 (27%) horses in the VAE oral group with complete ES regression, 3 (21%) in the VAE SC injection group, and 2 (13%) in the placebo group. The clinical response revealed complete or partial regression in 6 horses of the oral VAE group (40%), 4 of the SC injection group (29%), and 4 of the placebo group (25%). Direct comparison of oral VAE and placebo showed an odds ratio, stratified for prognosis of 2.16 (95%-CI: 0.45-10.42) and a P-value of 0.336. CONCLUSION AND CLINICAL IMPORTANCE: Oral administration of VAE is well tolerated. No statistically significant difference in the effectiveness of systemic VAE versus placebo against ES was found.

Indexed as

Horse DiseasesPlant ExtractsAdministration, OralAnimalsDouble-Blind MethodFemaleHorsesInjections, SubcutaneousMaleSarcoidosisSkin NeoplasmsViscum albumPlant Extractsequine sarcoidhorseimmunotherapymistletoerandomized trialViscum album extract

Identifiers

PMID38529853
PMCPMC11099770
OpenAlexW4393200071

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.